Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
News|Articles|September 4, 2026
Pharmacy Practice in Focus: Health Systems
- September 2026
- Volume 15
- Issue 5
The Real-World Practice Implications of the Expanding Frontier of Health System Pharmacy
Author(s)Mike Hennessy Jr, Chairman and CEO
Fact checked by: Ron Panarotti
This issue's content reflects a specialty that is clinically rigorous and structurally evolving.
Advertisement
Advertisement
As health system pharmacy continues to expand its footprint across the care
continuum, this issue of Pharmacy Practice in Focus: Health Systems captures just how far the profession has come and how much further it is positioned to go. From workforce development to emerging therapeutics to the growing role of artificial intelligence (AI), this month’s contributions from pharmacists reflect a specialty that is clinically rigorous and struct urally evolving.
Related to this article
A PharmD candidate reflects on the small, evidence-backed daily habits that helped her thrive—not just survive—through pharmacy school's most demanding years.
Understanding local health care priorities is essential to developing meaningful solutions.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Advertisement
Advertisement